Analyst: Lilly drug poised for continued growth
Eli Lilly and Co.'s lung cancer treatment Alimta is poised for continued growth based on recently released study data, according to a new Credit Suisse analyst report.
Cancer
Articles
Trade agency to probe Lilly’s infringement claim
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Head of Lilly’s oncology unit resigning
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
Lilly suspends late-stage trial for melanoma drug
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
Group says billboard companies rejected anti-Lilly ad
San Francisco-based Breast Cancer Action wanted its message, “Eli Lilly is making us sick. Tell them to stop,” posted on local billboards. But numerous sign companies refused, the group said.
Positron has billion-dollar hopes for medical-imaging scanner
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
Cancer researcher battling Semafore in court
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
WellPoint pledges two-day hospital stays after mastectomy
In the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay
for any breast cancer patient to stay two days in a hospital after surgery.
Purdue secures $15M to expand cancer research building
Stimulus dollars from the National Institutes of Health expected to spark 30 to 40 new research jobs by 2013.
DAVIS: Finding (and keeping) clarity through cancer
Almost eight months ago, I used this space to share the new perspective on life I discovered as a side effect of my battle
with cancer. A lot has happened since then, and I’m still marveling at the difference—even as I struggle to hold
onto it.
Health care bill burns local tanning industry
With one of the nation’s largest tanning-bed manufacturers and dozens of salons in central Indiana, a 10-percent tax on tanning
could cost the region jobs.
IU cancer center names new director
Dr. Patrick J. Loehrer Sr. replaces Dr. Stephen D. Williams, the center’s founding director, who died of cancer in February
2009.
House approves smoking ban in public places
The House has approved legislation that would ban smoking in public places statewide except casinos and pari-mutuel horse
racing venues.
Enzon Pharmaceuticals sells Indy drug plant; 100 local jobs safe
New Jersey-based Enzon Pharmaceuticals Inc. has sold its Indianapolis plant that manufactures specialty drugs in a deal that
could top $300 million. The buyer says that the operations, which employ about 100, will remain in the city.
HICKS: New breast cancer recommendation not supported
Under the current proposal, the same type of groups that made the CDC’s recommendations will outline guidelines about which treatment will be offered under a government program.
Indy Chamber of Commerce endorses smoking ban
The Indianapolis Chamber of Commerce is throwing its weight behind a tougher workplace smoking ban up for consideration tonight
by the City-County Council.
Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Endocyte receives $26M infusion from investors
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
Lilly: Alimta improves lung-cancer survival time
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.